Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
2020 · New England Journal of Medicine · 1,443 citations
https://doi.org/10.1056/nejmoa2002788
B
Begoña P. Valderrama
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
171
Papers
6.6K
Citations
25
h-index
51
i10-index
Begoña P. Valderrama is an academic researcher from Hospital Universitario Virgen del Rocío. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers & Urinary and Genital Oncology Studies. The author has an h-index of 25, co-authored 146 publications.
ORCID: 0000-0003-0175-1263Papers by this author
worksEnfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · New England Journal of Medicine · 810 citations
https://doi.org/10.1056/nejmoa2312117
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024 · Journal of Clinical Oncology · 137 citations
https://doi.org/10.1200/jco.23.01569
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial
2023 · European Urology · 55 citations
https://doi.org/10.1016/j.eururo.2023.03.030
SEOM clinical guideline for treatment of kidney cancer (2019)
2020 · Clinical & Translational Oncology · 27 citations
https://doi.org/10.1007/s12094-019-02285-7
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
2023 · European Urology · 23 citations
https://doi.org/10.1016/j.eururo.2023.01.016
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat